Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFG316 and IVIG Interaction in ESRD Patients Awaiting Kidney Transplant
NCT02878616Phase 1Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tesidolumab in kidney transplantation (2 arms), sponsored by Novartis. Primary endpoints: Area Under the Plasma Concentration-time Curve at 1 month and Observed Maximum Plasma Concentration Following Drug Administration at 1 month. Started Aug 2016; status: completed.
02
Drugs
tesidolumab
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT02878616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878616.